<p>Champions Oncology（CSBR）召開了第二季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
<h3>享受 TipRanks Premium 50% 折扣，安心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
<p>Champions Oncology 最近的財報電話會議描繪了強勁的財務健康狀況，年同比收入增長顯著，毛利率提升。公司正在對放射性標記和數據平台進行戰略投資，預計將推動長期增長。儘管這些積極指標存在，但增加的運營費用和現金流挑戰被強調為關注領域。總體而言，會議的情緒表明對 Champions Oncology 的前景持樂觀態度。</p>
<h2>年同比收入增長</h2>
<p>Champions Oncology 報告第二季度收入為 1500 萬美元，比去年 1350 萬美元增長 11%。這一增長主要得益於已預定工作的轉化率提升，展示了公司利用市場機會的能力。</p>
<h2>毛利率改善</h2>
<p>公司實現了 52% 的毛利率，較去年 45% 上升。這一改善歸因於運營效率和穩定的銷售成本，反映了 Champions Oncology 的有效管理策略。</p>
<h2>放射性標記和放射藥物的成功</h2>
<p>Champions Oncology 在放射性標記和放射藥物支持工作流程方面持續表現出色，使公司在腫瘤藥物開發市場中獨樹一幟。這一成功凸顯了其競爭優勢和未來增長的潛力。</p>
<h2>對數據平台的投資</h2>
<p>公司正在積極投資於其數據平台，以增強功能並更好地支持製藥合作伙伴。這一戰略舉措引起了客户的極大興趣，表明未來收入來源的良好前景。</p>
<h2>正向調整後 EBITDA</h2>
<p>Champions Oncology 正在朝着實現全年正向調整後 EBITDA 的目標邁進，與其 2026 財年的核心財務目標一致。這一里程碑反映了公司對財務穩定和增長的承諾。</p>
<h2>運營費用增加</h2>
<p>與去年相比，運營費用增加了 200 萬美元，主要由於對數據平台和其他戰略優先事項的投資。儘管這一增長顯著，但與公司的增長戰略相符。</p>
<h2>現金流挑戰</h2>
<p>公司面臨現金流挑戰，運營活動淨現金使用額達到 190 萬美元。這主要是由於遞延收入的減少，突顯了需要關注的領域。</p>
<h2>前瞻性指導</h2>
<p>首席執行官 Robert Brainin 提供了未來幾個季度的指導，強調繼續實現年同比收入增長和保持全年正向調整後 EBITDA 的目標。公司擁有 850 萬美元現金且無債務，專注於利用其放射性標記能力和擴展數據平台以推動長期增長。管理層對未來表現持樂觀態度，得益於市場條件的改善和客户參與度的提升。</p>
<p>總之，Champions Oncology 的財報電話會議反映了積極的財務軌跡，得益於戰略投資和運營效率。儘管存在運營費用增加和現金流問題等挑戰，但公司的強勁收入增長和獨特的市場定位表明前景樂觀。投資者和利益相關者可以對 Champions Oncology 的未來表現保持樂觀。</p>

CSBR

<p>Champions Oncology 公佈了強勁的第二季度財務業績，收入增長 11%，達到 1500 萬美元，毛利率提升至 52%。在放射性標記和數據平台方面的戰略投資預計將推動長期增長。儘管運營費用增加和現金流面臨挑戰，公司仍致力於持續的收入增長和正向調整後的息税折舊攤銷前利潤（EBITDA）。管理層手握 850 萬美元現金且無債務，對未來表現保持樂觀，得益於市場條件的改善和客户參與度的提升</p>

<p>Champions Oncology ((CSBR)) has held its Q2 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Champions Oncology（CSBR）召開了第二季度財報電話會議。請繼續閲讀會議的主要亮點。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，安心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的狀態</li>
</ul>
</div><p>Champions Oncology’s recent earnings call painted a picture of robust financial health, with notable year-over-year revenue growth and enhanced gross margins. The company is making strategic investments in radiolabeling and its data platform, which are anticipated to fuel long-term growth. Despite these positive indicators, increased operating expenses and cash flow challenges were highlighted as areas of concern. Overall, the sentiment from the call suggests a favorable outlook for Champions Oncology.</p>
<div class="lb-trans"><p>Champions Oncology 最近的財報電話會議描繪了強勁的財務健康狀況，年同比收入增長顯著，毛利率提升。公司正在對放射性標記和數據平台進行戰略投資，預計將推動長期增長。儘管這些積極指標存在，但增加的運營費用和現金流挑戰被強調為關注領域。總體而言，會議的情緒表明對 Champions Oncology 的前景持樂觀態度。</p>
</div><h2>Year-over-Year Revenue Growth</h2>
<div class="lb-trans"><h2>年同比收入增長</h2>
</div><p>Champions Oncology reported a revenue of $15 million for the second quarter, marking an 11% increase from the previous year’s $13.5 million. This growth was primarily driven by improved conversion of booked work, showcasing the company’s ability to capitalize on its market opportunities.</p>
<div class="lb-trans"><p>Champions Oncology 報告第二季度收入為 1500 萬美元，比去年 1350 萬美元增長 11%。這一增長主要得益於已預定工作的轉化率提升，展示了公司利用市場機會的能力。</p>
</div><h2>Improved Gross Margin</h2>
<div class="lb-trans"><h2>毛利率改善</h2>
</div><p>The company achieved a gross margin of 52%, up from 45% last year. This improvement was attributed to operational efficiencies and a stable cost of sales, reflecting Champions Oncology’s effective management strategies.</p>
<div class="lb-trans"><p>公司實現了 52% 的毛利率，較去年 45% 上升。這一改善歸因於運營效率和穩定的銷售成本，反映了 Champions Oncology 的有效管理策略。</p>
</div><h2>Radiolabeling and Radiopharmaceutical Success</h2>
<div class="lb-trans"><h2>放射性標記和放射藥物的成功</h2>
</div><p>Champions Oncology continues to excel in radiolabeling and radiopharmaceutical support workflows, which positions the company uniquely within the oncology drug development market. This success underscores its competitive edge and potential for future growth.</p>
<div class="lb-trans"><p>Champions Oncology 在放射性標記和放射藥物支持工作流程方面持續表現出色，使公司在腫瘤藥物開發市場中獨樹一幟。這一成功凸顯了其競爭優勢和未來增長的潛力。</p>
</div><h2>Investment in Data Platform</h2>
<div class="lb-trans"><h2>對數據平台的投資</h2>
</div><p>The company is actively investing in its data platform to enhance functionality and better support pharmaceutical partners. This strategic move has garnered significant customer interest, indicating a promising avenue for future revenue streams.</p>
<div class="lb-trans"><p>公司正在積極投資於其數據平台，以增強功能並更好地支持製藥合作伙伴。這一戰略舉措引起了客户的極大興趣，表明未來收入來源的良好前景。</p>
</div><h2>Positive Adjusted EBITDA</h2>
<div class="lb-trans"><h2>正向調整後 EBITDA</h2>
</div><p>Champions Oncology is on track to achieve a full-year positive adjusted EBITDA, aligning with its core financial goals for fiscal 2026. This milestone reflects the company’s commitment to financial stability and growth.</p>
<div class="lb-trans"><p>Champions Oncology 正在朝着實現全年正向調整後 EBITDA 的目標邁進，與其 2026 財年的核心財務目標一致。這一里程碑反映了公司對財務穩定和增長的承諾。</p>
</div><h2>Increased Operating Expenses</h2>
<div class="lb-trans"><h2>運營費用增加</h2>
</div><p>Operating expenses rose by $2 million compared to last year, mainly due to investments in the data platform and other strategic priorities. While this increase is notable, it aligns with the company’s growth strategy.</p>
<div class="lb-trans"><p>與去年相比，運營費用增加了 200 萬美元，主要由於對數據平台和其他戰略優先事項的投資。儘管這一增長顯著，但與公司的增長戰略相符。</p>
</div><h2>Cash Flow Challenges</h2>
<div class="lb-trans"><h2>現金流挑戰</h2>
</div><p>The company faced cash flow challenges, with net cash used in operating activities amounting to $1.9 million. This was primarily driven by a decrease in deferred revenue, highlighting an area that requires attention.</p>
<div class="lb-trans"><p>公司面臨現金流挑戰，運營活動淨現金使用額達到 190 萬美元。這主要是由於遞延收入的減少，突顯了需要關注的領域。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指導</h2>
</div><p>CEO Robert Brainin provided guidance for the upcoming quarters, emphasizing the aim for continued year-on-year revenue growth and maintaining positive adjusted EBITDA for the full year. With $8.5 million in cash and no debt, the company is focused on leveraging its radiolabeling capabilities and expanding its data platform to drive long-term growth. Management remains optimistic about future performance, supported by improving market conditions and increasing customer engagement.</p>
<div class="lb-trans"><p>首席執行官 Robert Brainin 提供了未來幾個季度的指導，強調繼續實現年同比收入增長和保持全年正向調整後 EBITDA 的目標。公司擁有 850 萬美元現金且無債務，專注於利用其放射性標記能力和擴展數據平台以推動長期增長。管理層對未來表現持樂觀態度，得益於市場條件的改善和客户參與度的提升。</p>
</div><p>In summary, Champions Oncology’s earnings call reflects a positive financial trajectory, driven by strategic investments and operational efficiencies. While challenges such as increased operating expenses and cash flow issues exist, the company’s strong revenue growth and unique market positioning suggest a promising outlook. Investors and stakeholders can remain optimistic about Champions Oncology’s future performance.</p>
<div class="lb-trans"><p>總之，Champions Oncology 的財報電話會議反映了積極的財務軌跡，得益於戰略投資和運營效率。儘管存在運營費用增加和現金流問題等挑戰，但公司的強勁收入增長和獨特的市場定位表明前景樂觀。投資者和利益相關者可以對 Champions Oncology 的未來表現保持樂觀。</p>
</div>

Champions Oncology 在戰略投資的推動下報告了強勁的增長